Daily Endocrinology Research Analysis
Three papers stand out in endocrinology and metabolic research today: a translational study in Gut links a microbiota-derived metabolite (3-hydroxyanthranilic acid) and dopaminergic signaling to attention deficits in obesity; a mechanistic study in Molecular Metabolism shows intestinal stretch acutely suppresses feeding and improves glucose tolerance independent of GLP-1, with obesity-induced impairment reversed by weight loss and enhanced after sleeve gastrectomy; and a meta-analysis indicates
Summary
Three papers stand out in endocrinology and metabolic research today: a translational study in Gut links a microbiota-derived metabolite (3-hydroxyanthranilic acid) and dopaminergic signaling to attention deficits in obesity; a mechanistic study in Molecular Metabolism shows intestinal stretch acutely suppresses feeding and improves glucose tolerance independent of GLP-1, with obesity-induced impairment reversed by weight loss and enhanced after sleeve gastrectomy; and a meta-analysis indicates tirzepatide drives clinically meaningful weight loss, particularly in individuals without diabetes, with acceptable safety.
Research Themes
- Microbiome–metabolite–brain axis in obesity
- Gut mechanosensation regulating appetite and glucose homeostasis
- Incretin-based pharmacotherapy efficacy across diabetes status
Selected Articles
1. Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity.
Across three human cohorts with metagenomics and targeted tryptophan metabolomics, obesity was consistently linked to poorer attention. Functional validation with multiple mouse FMT experiments supports a causal role of gut microbiota and implicates the metabolite 3‑hydroxyanthranilic acid and dopaminergic signaling as modulators of attention.
Impact: This study integrates human multi-omics with preclinical causality to reveal a microbiota–metabolite–brain pathway affecting attention in obesity, identifying 3-HAA as a tractable target.
Clinical Implications: While not practice-changing yet, the findings suggest assessing cognitive symptoms in obesity care and exploring microbiota or 3-HAA–targeted interventions to improve attention.
Key Findings
- Obesity was consistently associated with reduced attention across three independent human cohorts.
- Plasma tryptophan metabolomics and metagenomics implicated 3‑hydroxyanthranilic acid and dopaminergic signaling in attention regulation.
- Multiple mouse FMT experiments provided functional validation supporting a causal role of the gut microbiota and 3‑HAA in modulating attention.
Methodological Strengths
- Three independent human cohorts with shotgun metagenomics and targeted metabolomics
- Preclinical functional validation via multiple FMT experiments to support causality
Limitations
- Human components are observational, limiting causal inference without intervention in people
- Specific microbial taxa and effect sizes are not fully detailed in the abstract; generalizability across populations remains to be determined
Future Directions: Conduct interventional trials modulating microbiota or 3‑HAA in people with obesity to test cognitive and attention outcomes and delineate dopaminergic pathways.
BACKGROUND: Obesity-related alterations in the gut microbiota have been linked to cognitive decline, yet their relationship with attention remains poorly understood. OBJECTIVE: To evaluate the possible relationships among gut metagenomics, plasma metabolomics and attention. DESIGN: We conducted faecal shotgun metagenomics and targeted plasma tryptophan metabolomics across three independent cohorts (n=156, n=124, n=804) with functional validations in preclinical models, including three faecal microbiota transplantation (FMT) experiments in mice and RESULTS: Obesity was consistently associated with reduced attention. Metagenomics analyses identified CONCLUSIONS: We have identified the microbiota and 3-HAA as potential therapeutic targets to improve attention, especially in obesity.
2. Weight loss reverses obesity-associated impairments in acute gastrointestinal stretch-induced suppression of food intake and glucose homeostasis.
Selective intestinal stretch via mannitol acutely suppressed feeding and improved oral glucose tolerance in mice independent of GLP‑1 signaling and vagal mechanosensation. Diet-induced obesity blunted these effects and NTS activation, which were restored after weight loss (dietary or VSG), with sleeve gastrectomy augmenting NTS responses to oral glucose.
Impact: Defines a GLP‑1–independent mechanosensory pathway linking intestinal stretch to feeding and glucose control, offering mechanistic insight into obesity-related dysregulation and bariatric surgery effects.
Clinical Implications: Findings suggest therapeutic opportunities to harness gut mechanosensation (beyond GLP‑1) and inform patient counseling on how weight loss and sleeve gastrectomy may restore central responses to intestinal signals.
Key Findings
- Intestinal stretch acutely suppressed food intake and improved oral glucose tolerance independent of GLP‑1 signaling and vagal intestinal mechanosensation.
- Diet-induced obesity impaired stretch-induced suppression of feeding and attenuated NTS neuronal activation.
- Dietary and surgical weight loss restored stretch responsiveness; VSG enhanced NTS activation to oral (but not IP) glucose.
Methodological Strengths
- Multiple complementary approaches (behavior, glucose tolerance, neural activation) in defined physiological states (lean, obese, post–weight loss)
- Mechanistic dissection using chemogenetics of vagal afferents and genetic/pharmacologic ablation of GLP‑1 signaling
Limitations
- Preclinical mouse study; translation to humans remains to be demonstrated
- Specific molecular mechanosensors mediating the effect were not identified
Future Directions: Identify the molecular mechanosensors and test stretch-mimetic or device-based interventions in humans to modulate appetite and glucose control.
OBJECTIVE: Chemical and mechanical signals from the gastrointestinal tract are critical for regulating satiety and glucose metabolism. While both nutrient sensing in the intestine and gastric distension has been well studied, the role of intestinal stretch in these metabolic processes remain unclear. This study evaluates the role of intestinal stretch in regulating food intake and glucose homeostasis in the context of normal body weight, obesity, and weight loss occurring via both dietary intervention and vertical sleeve gastrectomy (VSG). METHODS: We used the nonnutritive substance mannitol to selectively induce intestinal stretch in conscious mice. We assessed food intake, glucose tolerance, and neuronal activation in mice with normal body weight, obesity, or after dietary or surgically-induced weight loss. We employed chemogenetic approaches to inhibit GLP-1R and OxtR-expressing vagal afferents, and genetic and pharmacological strategies to ablate GLP-1 signaling to explore mechanisms for mannitol-induced suppression of feeding. RESULTS: Mannitol-induced intestinal stretch acutely suppressed food intake and improved oral glucose tolerance independent of GLP-1 signaling and vagal intestinal mechanosensation. Diet induced obesity impairs mannitol-induced intestinal stretch reductions in food intake and attenuates neuronal activation in the nucleus of the solitary tract (NTS) upon induction of intestinal stretch. Both dietary and surgical weight loss restored intestinal stretch-induced feeding suppression and enhanced NTS neuronal activation. Importantly, VSG heightened NTS neuronal activation in response to oral but not IP glucose. CONCLUSIONS: Together, these data demonstrate that intestinal stretch contributes to the regulation of feeding and glucose metabolism independently of intestinal nutrient-sensing or classical gut hormones.
3. Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.
Across randomized trials, tirzepatide produced statistically significant, clinically meaningful weight loss versus placebo, with larger effects in individuals without diabetes than those with diabetes and an acceptable safety profile. Analyses stratified by diabetes status refine expectations for different patient groups.
Impact: Provides aggregated, stratified evidence on tirzepatide efficacy and safety for weight management, directly informing clinical decision-making across diabetic and non-diabetic populations.
Clinical Implications: Supports tirzepatide as an effective anti-obesity option, with particularly strong weight loss in non-diabetes; aids counseling, treatment selection, and expectation setting across patient subgroups.
Key Findings
- Tirzepatide achieved significant weight reduction versus placebo across randomized trials.
- Weight loss effects were larger in individuals without diabetes than in those with diabetes.
- Safety profile was acceptable in both subpopulations over study durations ≥26 weeks.
Methodological Strengths
- Systematic review and meta-analysis of randomized controlled trials with stratification by diabetes status
- Use of random-effects models and reporting of pooled effect sizes with confidence intervals
Limitations
- Abstract does not report specific effect sizes or heterogeneity metrics
- Total sample size across all included trials (including non-diabetes cohorts) is not specified in the abstract
Future Directions: Head-to-head trials versus other anti-obesity agents and longer-term safety/effectiveness studies across diabetes strata, including cardiometabolic outcomes.
AIMS: To conduct a systematic review and meta-analysis comparing tirzepatide versus placebo for weight management, with analyses stratified by diabetes status to precisely assess its efficacy and safety in individuals with and without diabetes. METHODS: We systematically searched MEDLINE, Embase, and Cochrane Library for randomized controlled trials comparing once-weekly tirzepatide (5-15 mg) versus placebo in adults with or without diabetes for at least 26 weeks. For each subpopulation analysis, the random-effects model was used to calculate pooled risk ratios (RRs) and mean differences (MDs), with their 95% confidence intervals, for dichotomous and continuous endpoints, respectively. Statistical significance was considered at p < 0.05. RESULTS: We included five trials (n = 2,174) in patients with diabetes (BMI ≥ 23 kg/m CONCLUSIONS: Compared with placebo, tirzepatide resulted in statistically significant and clinically meaningful weight reduction, especially in patients without diabetes (with overweight/obesity), with an acceptable safety profile.